• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Generation Bio Co. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/7/25 4:10:12 PM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GBIO alert in real time by email
    Generation Bio Co._May 7, 2025
    0001733294false00017332942025-05-072025-05-07

    ​

    ​

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

    FORM 8-K

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of report (Date of earliest event reported): May 7, 2025

    Generation Bio Co.

    (Exact Name of Registrant as Specified in Charter)

    ​

    Delaware

        

    001-39319

        

    81-4301284

    (State or Other Jurisdiction

    of Incorporation)

    ​

    (Commission

    File Number)

    ​

    (IRS Employer

    Identification No.)

    ​

    ​

    301 Binney Street

    Cambridge, MA

        

    02142 

    (Address of Principal Executive Offices)

    ​

    (Zip Code)

    ​

    Registrant’s telephone number, including area code: (617) 655-7500

    Not applicable

    (Former Name or Former Address, if Changed Since Last Report)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

    ​

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ​

    ​

    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ​

    ​

    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ​

    ​

    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    ​

    Securities registered pursuant to Section 12(b) of the Act:

    ​

    ​

    ​

    Title of each class

        

    Trading Symbol(s)

        

    Name of each exchange on which registered

    Common Stock, $0.0001 par value per share

    ​

    GBIO

    ​

    Nasdaq Global Select Market

    ​

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company  ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

    ​

    ​

    Item 2.02 Results of Operations and Financial Condition.

    On May 7, 2025, Generation Bio Co. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended March 31, 2025. A copy of this press release is furnished as Exhibit 99.1 and is incorporated herein by reference.

    The information in this Item 2.02 on Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company, under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filling.

    ​

    ​

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits

    Exhibit
    No.

      

    Description

    99.1

      

    Press Release Issued by Generation Bio Co. on May 7, 2025.

    104

    ​

    Cover Page Interactive Data File (embedded within the Inline XBRL document).

    ​

    ​

    ​

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    ​

    GENERATION BIO CO.

    Date: May 7, 2025

    By:

    /s/ Geoff McDonough

    Name: Geoff McDonough, M.D.

    Title: President and Chief Executive Officer

    ​

    ​

    ​

    Get the next $GBIO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GBIO

    DatePrice TargetRatingAnalyst
    10/19/2023Outperform → Market Perform
    TD Cowen
    11/8/2022$9.00Buy
    Canaccord Genuity
    12/15/2021$40.00 → $10.00Market Outperform
    JMP Securities
    12/15/2021$50.00 → $27.00Buy
    Needham
    12/14/2021Outperform → Mkt Perform
    William Blair
    More analyst ratings